// Lushuai Yao 1,2,* , Shancheng Ren 3,* , Minjie Zhang 1,2,* , Fengxia Du 1 , Yasheng Zhu 3 , Hui Yu 1,2 , Chenyu Zhang 1 , Xiaohua Li 1 , Caiyun Yang 1 , Huixian Liu 1 , Dong Wang 1,2 , Hao Meng 1,2 , Shuang Chang 1,2 , Xiao Han 1,2 , Yinghao Sun 3 and Yingli Sun 1 1 Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China 2 University of Chinese Academy of Sciences, Beijing, China 3 Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China * These authors have contribute equally to this work Correspondence to: Yingli Sun, email: // Yinghao Sun, email: // Keywords : DNA methylation, prostate cancer, Y-chromosome, biomarker Received : April 01, 2015 Accepted : September 26, 2015 Published : October 16, 2015 Abstract As a diagnostic biomarker, prostate special antigen (PSA) tests always generate false positive results and lead to unnecessary and/or repeat biopsies. Therefore, there is an urgent need for developing more sensitive, specific diagnostic biomarkers. We epigenotyped methylated sites in cancer tissues and adjacent normal tissues from 66 patients. In comparation with normal adjacent tissues, we observed that there were 6 aberrant methylation sites in prostate cancer tissues on the Y-chromosome. We further performed pyrosequencing using urine of PCa patients and we identified one methylated site (cg05163709) as a potential biomarker. We evaluated the predictive capacity of the aberrant methylated sites using the area under receiver operating characteristic (ROC) curve (AUC). The ROC analysis showed a higher AUC for cg05163709 (0.915) than prostate-specific antigen (PSA, 0.769). These results indicated that aberrant DNA methylation of cg05163709 on the Y-chromosome could serve as a potential diagnostic biomarker with high sensitivity and specificity.
Yao, L., Ren, S., Zhang, M., Du, F., Zhu, Y., Yu, H., … Sun, Y. (2015). Identification of specific DNA methylation sites on the Y-chromosome as biomarker in prostate cancer. Oncotarget, 6(38). https://doi.org/10.18632/oncotarget.6141